CompletedPHASE1, PHASE2NCT03366142

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Studying Leukocyte adhesion deficiency

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Beatriz E Marciano, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Intervention: Ustekinumab(drug)
Enrollment: 6 enrolled
Eligibility: 12-65 years · All sexes
Timeline: 2018 – 2024

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03366142 on ClinicalTrials.gov

Other trials for Leukocyte adhesion deficiency

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNCT06282432
Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I)
Rocket Pharmaceuticals Inc.

See all trials for Leukocyte adhesion deficiency →

← Back to all trials